T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
EMERYVILLE, Calif., April 27, 2017 -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that it will report its financial results for the first quarter ended March 31, 2017, after the market close, and will host a corporate update conference call and webcast on Thursday, May 4th, at 4:30 PM Eastern Time.
Thursday, May 4th @ 4:30 PM Eastern Time/1:30 PM Pacific Time
| Toll Free: | 888-287-5516 |
| International: | 719-325-2436 |
| Conference ID: | 2588025 |
| Webcast: | http://public.viavid.com/index.php?id=123895 |
Replays, available through May 18, 2017:
| Domestic: | 844-512-2921 |
| International: | 412-317-6671 |
| Replay PIN: | 2588025 |
About Zogenix
Zogenix, Inc. (Nasdaq:ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.
For more information, visit www.zogenix.com.
CONTACT: Investors: Andrew McDonald Founding Partner, LifeSci Advisors LLC 646-597-6987 | [email protected]
